Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
Mar 31, 2017 12:05 pm UTC| Business
NEW YORK and CLEVELAND, March 31, 2017 -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases,...
Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
Mar 31, 2017 12:01 pm UTC| Business
VANCOUVER, British Columbia, March 31, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases,...
Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
Mar 31, 2017 12:01 pm UTC| Business
VANCOUVER, British Columbia, March 31, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases,...
Omnitek Engineering Corp. Reports 2016 Results
Mar 31, 2017 12:01 pm UTC| Business
VISTA, Calif., March 31, 2017 -- Omnitek Engineering Corp. (OTCQB:OMTK) today reported results for its fourth quarter and year ended December 31, 2016. Revenues for the fourth quarter ended December 31, 2016 were...
Omnitek Engineering Corp. Reports 2016 Results
Mar 31, 2017 12:01 pm UTC| Business
VISTA, Calif., March 31, 2017 -- Omnitek Engineering Corp. (OTCQB:OMTK) today reported results for its fourth quarter and year ended December 31, 2016. Revenues for the fourth quarter ended December 31, 2016 were...
Mar 31, 2017 12:01 pm UTC| Business
ALPHARETTA, Ga. and MADISON, Wis., March 31, 2017 -- Clearside Biomedical Inc. (Nasdaq:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced...
Mar 31, 2017 12:01 pm UTC| Business
ALPHARETTA, Ga. and MADISON, Wis., March 31, 2017 -- Clearside Biomedical Inc. (Nasdaq:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced...